Duramed (A Subsidiary of Barr Pharmaceuticals) in Their Acquisition of FEI
Avant in the Identification and in-Licensing Transaction for CDX-1135 from Johns Hopkins Tech Transfer
an Undisclosed Round of Financing in a Private Placement for BioArbitrage Fund IV
Orphanetics in the Securitization of $65MM in Private Financing.
Alpine Immune Sciences in its Licensing Partnership with Abbvie for ALPN-101
EpiDestiny in its licensing partnership with Novo Nordisk for worldwide rights to EP101, an epigenetic treatment for SCD (Sickle Cell Disease)
G1 Therapeutics in its Out-Licensing Agreement with EQRx for lerociclib
Rib-X in the Identification and in-Licensing Transaction for Delafoxicin (Phase II) from Yale University
SymBio in its Divestiture to PerkinElmer
Forest Labs in the Identification and Licensing Transaction for U.S. Rights to Nycomed’s PDE-4 Inhibitor Daxas
BMS in the Identification and Securitization of a Strategic Alliance with Uniqure
Celgene in the Identification and Acquisition of Quanticel Pharmaceuticals
Refer yourself here or call us on 704 906 3402
